Method of treating cancer with an RPN2 gene expression inhibitor
US8106024B2 · kind B2 · utility
2Cited by
1References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 15, 2007 |
| Grant date | Jan 31, 2012 |
| Priority date | — |
| Expiry date | Aug 25, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention uses an RPN2 gene expression inhibitor as a cancer cell growth inhibitor, which further includes a drug showing an anti-cancer action if desired, and is administered in combination with atelocollagen if desired. In addition, the present invention is an anti-cancer agent including such cancer cell growth inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.